Quality of Life in CAR-T Cell Therapy
Hematology Reports · 10.06.2026 · 18 (3) · 40
DOI: 10.3390/hematolrep18030040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 10.06.2026. Verfasst von Caterina Alati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropol…. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning.
Objectives
Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape.
Conclusions
This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.
- Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, 00128 Rome, Italy.
ORCID-Profile: Martina Pitea, Erica Bilardi, Ilaria Maria Delfino, Filippo Antonio Canale, Massimo Martino
Zitieren
APA
Alati, C., Pitea, M., Porto, G., Policastro, G., Bilardi, E., Utano, G., Giordano, L., Sgarlata, A., Delfino, I. M., Idato, A., Santoro, G., Canale, F. A., Naso, V., & Martino, M. (2026). Quality of Life in CAR-T Cell Therapy. Hematology Reports, 18(3), 40. https://doi.org/10.3390/hematolrep18030040
Vancouver
Alati C, Pitea M, Porto G, Policastro G, Bilardi E, Utano G, et al. Quality of Life in CAR-T Cell Therapy. Hematology Reports. 2026;18(3):40. doi:10.3390/hematolrep18030040
BibTeX
@article{Alati2026,
author = {Alati, Caterina and Pitea, Martina and Porto, Gaetana and Policastro, Giorgia and Bilardi, Erica and Utano, Giovanna and Giordano, Laura and Sgarlata, Annalisa and Delfino, Ilaria Maria and Idato, Aurora and Santoro, Giulia and Canale, Filippo Antonio and Naso, Virginia and Martino, Massimo},
title = {Quality of Life in CAR-T Cell Therapy},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {3},
pages = {40},
doi = {10.3390/hematolrep18030040}
}
EUVIMED